Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now NasdaqCM - Nasdaq Real Time Price • USD Aytu BioPharma, Inc. (AYTU) Follow Add holdings 1.1100 +0.0100 +(0.91%) At close: April 25 at 4:00:00 PM EDT 1.0600 -0.05 (-4.50%) After hours: April 25 at 5:15:11 PM EDT All News Press Releases SEC Filings Aytu BioPharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025 Company to conduct 1x1 meetings on April 24, 2025 DENVER, CO / ACCESS Newswire / April 21, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced ... Loss-Making Aytu BioPharma, Inc. (NASDAQ:AYTU) Set To Breakeven With the business potentially at an important milestone, we thought we'd take a closer look at Aytu BioPharma, Inc.'s... Aytu BioPharma Inc (AYTU) Q2 2025 Earnings Call Highlights: Strong Cash Position and Strategic ... Aytu BioPharma Inc (AYTU) reports positive EBITDA and net income, while addressing ADHD revenue challenges and optimizing costs. Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced operational and financial results for the fiscal 2025 second quarter. Q2 2025 Highlights Quarterly ... Aytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025 Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its operational and financial results for its second quarter of fiscal 2025, after the market close on ... Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 DENVER, CO / ACCESSWIRE / January 6, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that CEO, Josh Disbrow, will participate in a webcasted ... Aytu BioPharma Proposes Settlement in Shareholder Lawsuit Aytu BioScience ( (AYTU) ) has issued an announcement. Aytu BioPharma, Inc. announced a proposed settlement in a shareholder derivative lawsuit involving accusations of fiduciary breaches and unjust enrichment by company directors and Armistice Capital. The lawsuit alleges that these parties orchestrated transactions benefiting themselves at the expense of Aytu shareholders. A court hearing is scheduled for January 2025 to determine the fairness of the settlement, which aims to resolve claims an Aytu BioPharma Disclosure Notification DENVER, CO / ACCESSWIRE / December 3, 2024 / SUMMARY NOTICE OF PENDENCY OF DERIVATIVE ACTION, AGREEMENT OF SETTLEMENT AND RELEASE WITH RESPECT TO CERTAIN PARTIES, AND SETTLEMENT HEARING IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE LITIGATION ... Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM) DENVER, CO / ACCESSWIRE / November 22, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced it ranked 380th on the Deloitte Technology Fast 500™, ... Aytu BioPharma First Quarter 2025 Earnings: Beats Expectations Aytu BioPharma ( NASDAQ:AYTU ) First Quarter 2025 Results Key Financial Results Revenue: US$16.6m (down 25% from 1Q... Aytu BioPharma Inc (AYTU) Q1 2025 Earnings Call Highlights: A Historic Quarter with Positive ... Aytu BioPharma Inc (AYTU) achieves its first-ever positive net income, while expanding its ADHD and pediatric portfolios amidst revenue challenges. Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results Net income of $1.5 million Adjusted EBITDA1 of $1.9 million ADHD Portfolio net revenue up 1% to $15.3 million Pediatric Portfolio net revenue up 54% sequentially $20.1 million cash balance at September 30, 2024 Organizational changes and operating ... Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024 DENVER, CO / ACCESSWIRE / November 6, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its operational and financial results for its first quarter ... Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit DENVER, CO / ACCESSWIRE / October 14, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced Josh Disbrow, Chief Executive Officer of Aytu, will ... Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada Once approved by Health Canada, Adzenys and Cotempla will be the only orally disintegrating, extended-release tablets for the treatment of ADHD commercialized in Canada DENVER, CO / ACCESSWIRE / October 1, 2024 / Aytu BioPharma, Inc. (the "Company" ... Aytu BioPharma Full Year 2024 Earnings: EPS Misses Expectations Aytu BioPharma ( NASDAQ:AYTU ) Full Year 2024 Results Key Financial Results Revenue: US$81.0m (down 25% from FY 2023... Q4 2024 Aytu Biopharma Inc Earnings Call Q4 2024 Aytu Biopharma Inc Earnings Call Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results Full year fiscal 2024 consolidated net revenue of $81.0 million; Rx Segment net revenue of $65.2 million Full year fiscal 2024 ADHD Portfolio net revenue up 23% compared to fiscal 2023 Full year fiscal 2024 adjusted EBITDA1 improved to $9.2 million, ... Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024 DENVER, CO / ACCESSWIRE / September 19, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its operational and financial results for its fiscal 2024 ... Analysts Expect Breakeven For Aytu BioPharma, Inc. (NASDAQ:AYTU) Before Long With the business potentially at an important milestone, we thought we'd take a closer look at Aytu BioPharma, Inc.'s... Performance Overview Trailing total returns as of 4/25/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) Return AYTU S&P 500 (^GSPC) YTD -34.71% -6.06% 1-Year -60.92% +9.44% 3-Year -91.46% +28.61%